These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30830540)

  • 1. Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy.
    Bloemendal M; van Willigen WW; Bol KF; Boers-Sonderen MJ; Bonenkamp JJ; Werner JEM; Aarntzen EHJG; Koornstra RHT; de Groot JWB; de Vries IJM; van der Hoeven JJM; Gerritsen WR; de Wilt JHW
    Ann Surg Oncol; 2019 Nov; 26(12):3945-3952. PubMed ID: 30830540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study.
    Madu MF; Timmerman P; Wouters MWJM; van der Hiel B; van der Hage JA; van Akkooi ACJ
    Melanoma Res; 2017 Jun; 27(3):251-257. PubMed ID: 28225434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrence patterns in patients with Stage II melanoma: The evolving role of routine imaging for surveillance.
    Bleicher J; Swords DS; Mali ME; McGuire L; Pahlkotter MK; Asare EA; Bowles TL; Hyngstrom JR
    J Surg Oncol; 2020 Dec; 122(8):1770-1777. PubMed ID: 33098702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance strategies in the follow-up of melanoma patients: too much or not enough?
    Kurtz J; Beasley GM; Agnese D; Kendra K; Olencki TE; Terando A; Howard JH
    J Surg Res; 2017 Jun; 214():32-37. PubMed ID: 28624057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma.
    Dieng M; Lord SJ; Turner RM; Nieweg OE; Menzies AM; Saw RPM; Einstein AJ; Emmett L; Thompson JF; Lo SN; Morton RL
    Ann Surg Oncol; 2022 May; 29(5):2871-2881. PubMed ID: 35142966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of FDG-PET/CT to detect early recurrence after resection of high-risk stage III melanoma.
    Stahlie EHA; van der Hiel B; Stokkel MPM; Schrage YM; van Houdt WJ; Wouters MW; van Akkooi ACJ
    J Surg Oncol; 2020 Dec; 122(7):1328-1336. PubMed ID: 32783266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma
    Koskivuo I; Kemppainen J; Giordano S; Seppänen M; Veräjänkorva E; Vihinen P; Minn H
    Acta Oncol; 2016 Nov; 55(11):1355-1359. PubMed ID: 27553064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients.
    Deckers EA; Wevers KP; Muller Kobold AC; Damude S; Vrielink OM; van Ginkel RJ; Been LB; van Leeuwen BL; Hoekstra HJ; Kruijff S
    J Surg Oncol; 2019 Nov; 120(6):1031-1037. PubMed ID: 31468535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma.
    Lewin J; Sayers L; Kee D; Walpole I; Sanelli A; Te Marvelde L; Herschtal A; Spillane J; Gyorki D; Speakman D; Estall V; Donahoe S; Pohl M; Pope K; Chua M; Sandhu S; McArthur GA; McCormack CJ; Henderson M; Hicks RJ; Shackleton M
    Ann Oncol; 2018 Jul; 29(7):1569-1574. PubMed ID: 29659679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
    Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJ; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Lupinacci R; Krepler C; Ibrahim N; Kicinski M; Marreaud S; van Akkooi AC; Suciu S; Robert C
    Eur J Cancer; 2019 Jul; 116():148-157. PubMed ID: 31200321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
    Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
    Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of surveillance imaging for resected high-risk melanoma.
    Yan MK; Adler NR; Wolfe R; Pan Y; Chamberlain A; Kelly J; Yap K; Voskoboynik M; Haydon A; Shackleton M; Mar VJ
    Asia Pac J Clin Oncol; 2023 Aug; 19(4):566-573. PubMed ID: 36540019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant vemurafenib in resected, BRAF
    Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
    Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
    Eggermont AM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Konto C; Hoos A; de Pril V; Gurunath RK; de Schaetzen G; Suciu S; Testori A
    Lancet Oncol; 2015 May; 16(5):522-30. PubMed ID: 25840693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma.
    Leon-Ferre RA; Kottschade LA; Block MS; McWilliams RR; Dronca RS; Creagan ET; Allred JB; Lowe VJ; Markovic SN
    Melanoma Res; 2017 Aug; 27(4):335-341. PubMed ID: 28296712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF
    Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM
    Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430.
    Sosman JA; Moon J; Tuthill RJ; Warneke JA; Vetto JT; Redman BG; Liu PY; Unger JM; Flaherty LE; Sondak VK
    Cancer; 2011 Oct; 117(20):4740-06. PubMed ID: 21455999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of initial staging PET-CT as a baseline scan for surveillance imaging in stage II and III melanoma.
    Ravichandran S; Nath N; Jones DC; Li G; Suresh V; Brys AK; Hanks BA; Beasley GM; Salama AKS; Howard BA; Mosca PJ
    Surg Oncol; 2020 Dec; 35():533-539. PubMed ID: 33161362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines.
    Romano E; Scordo M; Dusza SW; Coit DG; Chapman PB
    J Clin Oncol; 2010 Jun; 28(18):3042-7. PubMed ID: 20479405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results.
    Mackiewicz J; Burzykowski T; Iżycki D; Mackiewicz A
    J Immunother Cancer; 2018 Nov; 6(1):134. PubMed ID: 30486884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.